Immune checkpoint blockade: a common denominator approach to cancer therapy
Citations
4,569 citations
Cites background from "Immune checkpoint blockade: a commo..."
...Therapy with immune checkpoint inhibitors has uncovered a subset of tumors that are highly responsive to an endogenous adaptive immune response (1)....
[...]
3,246 citations
3,145 citations
3,131 citations
Cites background from "Immune checkpoint blockade: a commo..."
...Additional inhibitory immune checkpoints that are often expressed in the tumor microenvironment include LAG-3, TIGIT, VISTA, and many more that are being identified in ongoing studies (Topalian et al., 2015)....
[...]
2,920 citations
References
13,081 citations
"Immune checkpoint blockade: a commo..." refers background in this paper
..., 1996) led to the clinical development and approval of antiCTLA-4 as a treatment for patients with advanced melanoma (Hodi et al., 2010)....
[...]
...In 2011, ipilimumab was approved in the United States and Europe as therapy for advanced unresectable melanoma based on results from two phase III trials showing significant extensions in overall survival (OS) (Hodi et al., 2010; Robert et al., 2011)....
[...]
...…that blocking the prototypical immune checkpoint receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) could mediate tumor regression in murine models (Leach et al., 1996) led to the clinical development and approval of antiCTLA-4 as a treatment for patients with advanced melanoma (Hodi et al., 2010)....
[...]
10,674 citations
"Immune checkpoint blockade: a commo..." refers background in this paper
...Importantly, responseswere quite durable, with many persisting even after drug discontinuation, and long-term follow-up revealed OS of 9.9, 22.4, and 16.8 months, respectively (Topalian et al., 2014)....
[...]
6,812 citations
"Immune checkpoint blockade: a commo..." refers background in this paper
...…clinical development of PD-1 pathway-blocking drugs by multiple pharmaceutical and biotechnology companies (Table 1), and the clinical activity of these drugs in melanoma, RCC, and NSCLC has been confirmed (Brahmer et al., 2012; Hamid et al., 2013; Herbst et al., 2014; Motzer et al., 2014)....
[...]
5,129 citations
"Immune checkpoint blockade: a commo..." refers background in this paper
...…importance of PD-L1 expression by infiltrating immune cells (Herbst et al., 2014), the presence and location of CD8+ tumor-infiltrating lymphocytes (Tumeh et al., 2014), and other factors (Taube et al., 2014) are currently under intense study individually and in combination to discern more…...
[...]
4,602 citations
"Immune checkpoint blockade: a commo..." refers background in this paper
...A recent phase III report showed the superiority of first-line nivolumab versus standard chemotherapy in patients with advanced melanoma (Robert et al., 2015)....
[...]